Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
1989540 citationsCora N. Sternberg, Alan Yagoda et al.Cancerprofile →
Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium
1985513 citationsCora N. Sternberg, Alan Yagoda et al.The Journal of Urologyprofile →
M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium
1988492 citationsCora N. Sternberg, Alan Yagoda et al.The Journal of Urologyprofile →
Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study
2017270 citationsMichelle C. Janelsins, Charles E. Heckler et al.Journal of Clinical Oncologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Lora Weiselberg
Since
Specialization
Citations
This map shows the geographic impact of Lora Weiselberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lora Weiselberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lora Weiselberg more than expected).
This network shows the impact of papers produced by Lora Weiselberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lora Weiselberg. The network helps show where Lora Weiselberg may publish in the future.
Co-authorship network of co-authors of Lora Weiselberg
This figure shows the co-authorship network connecting the top 25 collaborators of Lora Weiselberg.
A scholar is included among the top collaborators of Lora Weiselberg based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Lora Weiselberg. Lora Weiselberg is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Janelsins, Michelle C., Charles E. Heckler, Luke J. Peppone, et al.. (2017). Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. Journal of Clinical Oncology. 35(5). 506–514.270 indexed citations breakdown →
Lichtman, Stuart M., Philip Schulman, Steven L. Allen, et al.. (1992). Use of Cisplatin for Elderly Patients. Age and Ageing. 21(3). 202–204.33 indexed citations
Kreis, Willi, Keith K. H. Chan, Steven L. Allen, et al.. (1991). Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.. PubMed. 5(11). 991–8.20 indexed citations
Weiselberg, Lora, Ursula A. Matulonis, Elizabeth L. McGarvey, et al.. (1990). Stereologic analysis of monocytes and their subcellular organelles in patients with acute monocytic and myelomonocytic leukemia.. PubMed. 63(3). 405–12.7 indexed citations
Sternberg, Cora N., Alan Yagoda, Howard I. Scher, et al.. (1989). Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 64(12). 2448–2458.540 indexed citations breakdown →
16.
Chan, Keith K. H., D. R. Budman, Philip Schulman, et al.. (1988). Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.. PubMed. 48(5). 1337–42.34 indexed citations
17.
Hakes, T., et al.. (1985). Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma.. PubMed. 69(5). 559–60.11 indexed citations
18.
Sternberg, Cora N., Alan Yagoda, Howard I. Scher, et al.. (1985). Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium. The Journal of Urology. 133(3). 403–407.513 indexed citations breakdown →
19.
Degnan, Thomas J., Lora Weiselberg, Philip Schulman, & Daniel R. Budman. (1984). Dysmyelopoietic syndrome. The American Journal of Medicine. 76(1). 122–128.18 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.